Drug Information

Drug General Information
Drug ID
D0B3ZC
Former ID
DIB000060
Drug Name
Claudiximab
Synonyms
IMAB-362; Anti-GC182 mAbs (cancer), Ganymed; Anti-GC182 monoclonal antibodies (cancer), Ganymed; Anti-CLDN18-2 mAbs (cancer), Ganymed; Anti-CLDN18-2 monoclonal antibodies (cancer), Ganymed
Drug Type
Antibody
Indication Esophageal cancer [ICD9: 150; ICD10:C15] Phase 2 [523164]
Company
Ganymed Pharmaceuticals AG
Target and Pathway
Target(s) Claudin 18 Target Info [532444]
KEGG Pathway Cell adhesion molecules (CAMs)
Tight junction
Leukocyte transendothelial migration
Hepatitis C
NetPath Pathway IL4 Signaling Pathway
Reactome Tight junction interactions
References
Ref 523164ClinicalTrials.gov (NCT01197885) Efficacy and Safety Study of Multiple Doses of IMAB362 in Patients With Advanced Gastroesophageal Cancer. U.S. National Institutes of Health.
Ref 532444Claudin 18.2 is a target for IMAB362 antibody in pancreatic neoplasms. Int J Cancer. 2014 Feb 1;134(3):731-9.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.